Literature DB >> 17173077

[Preparation and identification of monoclonal antibodies against human programmed cell death 10 (PDCD10)].

Yao-yao Chen1, Yun-gang Zhao, Ting Zhang, Lan-jun Xu, Xi Ma, Hong-shan Zhao, Ying-yu Chen.   

Abstract

OBJECTIVE: To obtain monoclonal antibodies against programmed cell death 10 (PDCD10) for further study of the structure and function of PDCD10 protein.
METHODS: Balb/c mice were immunized with recombinant PDCD10, hybridoma cell lines secreting monoclonal antibodies against PDCD10 were screened by regular cell fusion and subcloning approach. The specificities of these monoclonal antibodies were determined by ELISA, Western blotting and Immunofluorescence assay.
RESULTS: Three hybridoma cell lines (5G1, 4F7 and 3H5) stable in secreting specific monoclonal antibodies were successfully obtained. Subclass of IgG belonged to IgG1 (4F7 and 5G1) and IgG2b (3H5), respectively. The ascite titers of these monoclonal antibodies reached 1:10(7). They could specifically bind to recombinant PDCD10 and endogenous and overexpressed PDCD10 proteins proved by ELISA and Western blotting. They failed to react with E.coli lysates and glutathione S-transferase (GST). In addition, these three monoclonal antibodies could recognize different epitopes of PDCD10 proteins assessed by immune fluorescence competitive binding assay. Both endogenous and overexpressed PDCD10 protein mainly located in the nucleus.
CONCLUSION: Monoclonal antibodies against PDCD10 with high titers and specificity have been successfully prepared, which has laid the foundation for further study of PDCD10 protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17173077

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  1 in total

1.  Differential expression of MST4, STK25 and PDCD10 between benign prostatic hyperplasia and prostate cancer.

Authors:  Heyu Zhang; Xi Ma; Saihui Peng; Xu Nan; Hongshan Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.